Adriamycin-induced myocardial toxicity: New solutions for an old problem?

International Journal of Cardiology

Volumn 117, Issue 1, 2007, Pages 6-15

  Outomuro, Delia ^a   Grana, Daniel R ^a   Azzato, Francisco ^a   Milei, José ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Adriamycin; Cardiomyopathy; Myocardial toxicity

Indexed keywords

ALPHA TOCOPHEROL; ANTHRACYCLINE DERIVATIVE; ANTIOXIDANT; BUTYLATED HYDROXYANISOLE; CAPTOPRIL; CENTELLA ASIATICA EXTRACT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; FREE RADICAL; IRON; LIPOSOME; MACROGOL; MELATONIN; MITOXANTRONE; PLACEBO; PREDNISOLONE; RAZOXANE; RETINOL; SODIUM TANSHINONE 2A; TEMOCAPRIL; UNCLASSIFIED DRUG; VALSARTAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DNA DAMAGE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG POTENTIATION; HEART FUNCTION; HEART MUSCLE INJURY; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; LIPID PEROXIDATION; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; MOUSE STRAIN; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RABBIT; REVIEW; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG EVALUATION; DRUG TOXICITY; HUMANS; NEOPLASMS;

EID: 33947128057     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.05.005     Document Type: Review

References (99)

1. Mordente A., Meucci E., Martorana G.E., Giardina B., and Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52 (2001) 83-88
2. Di Marco A., Gaetani M., and Scarpinato B. Adriamycin (NSC-123127): a new antibiotic with antitumor activity. Cancer Chemother Rep 53 (1969) 33-37
3. Petit T. Anthracycline-induced cardiotoxicity. Bull Cancer 91 (2004) 159-165
4. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 8 (2003) 17-24
5. Wallace K.B. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93 (2003) 105-115
6. Von Hoff D.D., Layard M.W., and Basa P. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 (1979) 710-717
7. Prout N.M., Richards M.J.S., and Chung J.K. Adriamycin cardiotoxicity in children: case reports. Cancer 39 (1977) 62-65
8. Appelbaum F.R., Strauchen J.A., Uraw Jr. R.U., et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1 (1976) 58
9. Minow R.A., Benjamin R.S., and Lee E.I. Adriamycin cardiomyopathy: risk factors. Cancer 39 (1977) 1397-1402
10. Simsis S.A., Lin S.S., Blue L.J., Gockerman J.P., Russell S.D., and Milano C.A. Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyophaty. Ann Thorac Surg 80 (2005) 717-719
11. Ferrero M.E., Ferrero E., and Gaja U. Adriamycin: energy metabolism and mitochondrial oxidations in the heart of treated rabbits. Biochem Pharmacol 25 (1976) 125-130
12. Gozalvez M., and Blanco M. Inhibition of NA-K ATPase by the antitumor antibiotic adriamycin. 5th International Biophysics Congress, Copenhagen (1975)
13. Di Marco A. Adriamycin (NSC-123 127): mode and mechanism of action. Cancer Chemother Rep 6 (1975) 91-106
14. Kishi T., and Folkers K. Prevention by coenzyme Q10 of the inhibition of adriamycin of coenzyme Q10 enzymes. Cancer Treat Rep 60 (1976) 223-228
15. Lenaz L., and Page J.A. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3 (1976) 111-120
16. Lou H., Danelisen I., and Singal P.K. Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. J Mol Cell Cardiol 36 (2004) 683-690
17. Earm Y.E., Ho W.K., and So I. Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit. J Mol Cell Cardiol 26 (1994) 163-172
18. Al-Nasser I.A. In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506. Toxicology 131 (1998) 175-181
19. Nagami K., Yoshikawa T., Suzuki M., Wainai Y., Anzai T., and Handa S. Abnormal beta-adrenergic transmembrane signaling in rabbits with adriamycin-induced cardiomyopathy. Jpn Circ J 61 (1997) 249-255
20. Milei J., Boveris A., Llesuy S., et al. Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am Heart J 111 (1986) 95-102
21. Milei J., and Llesuy S. Reduction in the toxicity of doxorubicin (adriamycin) in the heart by vitamin E. In: Packer L., and Fuchs J. (Eds). Vitamin E in health and disease (1993), Marcel Dekker Inc, New York 417-431 Chap 31
22. Chaiswing L., Cole M.P., St Clair D.K., Ittarat W., Szweda L.I., and Oberley T.D. Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol Pathol 32 (2004) 536-547
23. Oliveira P.J., Bjork J.A., Santos M.S., et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 200 (2004) 159-168
24. Papadopoulou L.C., Theophilidis G., Thomopoulos G.N., and Tsiftsoglou A.S. Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. Biochem Pharmacol 57 (1999) 481-489
25. Yen H.C., Oberley T.D., Gairola C.G., Szweda L.I., and St Clair D.K. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys 362 (1999) 59-66
26. Kojima S., Iizuka H., Yamaguchi H., Tanuma S., Kochi M., and Ueno Y. Antioxidative activity of benzylideneascorbate and its effect on adriamycin-induced cardiotoxicity. AntiCancer Res 14 (1994) 1875-1880
27. Bagchi D., Bagchi M., Hassoun E.A., Kelly J., and Stohs S.J. Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology 95 1-3 (1995) 1-9
28. Muraoka S., and Miura T. Free radicals mediate cardiac toxicity induced by adriamycin. Yakugaku Zasshi 123 (2003) 855-866
29. Sato 5, Iwaizmi M., Hauda K., and Tamura J. Electron spin rcsonance study on the mode of generation of free radicals of daunomycin, adriamycin and carboquone in NAD(P) H-microsome system. Gann 68 (1977) 603-608
30. Llesuy 5, Milei J., Molina H., Boveris A., and Milei S. Comparison of lipid peroxidation and myocardial damage induced by adriamycin and 4′epiadriarnycin in mice. Tumori 71 (1985) 241-249
31. Hrushesky W.J.M., Olshefski R.S., Wood P.A., Mechnik S., and Eaton 3W. Methylene blue ameliorates anthracycline toxicity. Clin Res 31 (1983) 778A-785A
32. Szenczi O., Kemecsei P., Holthuijsen M.F., et al. Poly (ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol 69 (2005) 725-732
33. Tokarska-Schlattner M., Zaugg M., da Silva R., et al. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. Am J Physiol Heart Circ Physiol 289 (2005) 37-47
34. De Atley S.M., Aksenov M.Y., Aksenova M.V., Jordan B., Carney J.M., and Butterfield D.A. Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology 134 (1999) 51-62
35. Henderson I.C., and Frei E. Adriamycin and the heart. N Engl J Med 300 (1979) 310-311
36. Ferrans V. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62 (1978) 955-961
37. Myers C.E., McGuire W.P., and Liss R.H. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197 (1977) 165-166
38. Henderson I.C., and Frei E. Adriamycin cardiotoxicity. Am Heart J 99 (1980) 671
39. Kumar D., Kirshenbaum L.A., Li T., Danelisen I., and Singal P.K. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 3 (2001) 135-145
40. Nakamura T., Ueda Y., Juan Y., Katsuda S., Takahashi H., and Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study. Circulation 102 (2000) 572-578
41. Kumar D., Lou H., and Singal P.K. Oxidative stress and apoptosis in heart dysfunction. Herz 27 (2002) 662-668
42. Bristow M.R., Lopez M.B., and Mason J.W. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 50 (1982) 32-41
43. Young R.C., Ozols R.F., and Myers C.E. The anthracycline antineoplastic drugs. N Engl J Med 305 (1981) 139-153
44. Torti F.M., Bristow M.R., and Howes A.E. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endocardial biopsy. Ann Intern Med 99 (1983) 745-749
45. Lores Arnaiz S., and Llesuy S. Oxidative stress in mouse heart by antitumoral drugs: a comparative study of doxorubicin and mitoxantrone. Toxicology 77 (1993) 31-38
46. Philips E.S., Gilladoga A., and Marquardt H. Some observations on the toxicity of adriamycin (NSC123127). Cancer Chemother Rep 6 (1975) 177-181
47. Milei J., Bolomo N.J., and Marantz A. Prenylamine inhibition of adriamycin-induced cardiomyopathy in mice. Medicina (B Aires) 42 (1982) 409-414
48. Bristow M.R., Billingham M.E., Minobe W.A., Masck M.A., and Daniels J.R. Demonstration that adriamycin cardiotoxicity is mediated by vasoactive amines. J Mol Cell Cardiol 2 (1979) 10
49. Estevez M.D., Wolf A., and Schramm U. Effect of PSC 833, verapamil and amiodarone on adriamycin toxicity in cultured rat cardiomyocytes. Toxicol In Vitro 14 (2000) 17-23
50. Mohamed H.E., El-Sw Estevez efy S.E., and Hagar H.H. The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats. Pharmacol Res 42 (2000) 115-121
51. el-Missiry M.A., Othman A.I., Amer M.A., and Abd el-Aziz M.A. Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats. Free Radic Res 35 (2001) 575-581
52. Balachandar A.V., Malarkodi K.P., and Varalakshmi P. Protective role of dl-alpha-lipoic acid against adriamycin-induced cardiac lipid peroxidation. Hum Exp Toxicol 22 (2003) 249-254
53. Ma S.F., Guan S.D., and Zhu Y. Effect of soybean isoflavones on heart function of rats with adriamycin-induced heart failure. Zhong Xi Yi Jie He Xue Bao 2 (2004) 278-280
54. Kojima S., Icho T., Hayashi M., Kajiwara Y., Kitabatake K., and Kubota K. Inhibitory effect of 5,6,7,8-tetrahydroneopterin on adriamycin-induced cardiotoxicity. J Pharmacol Exp Ther 266 (1993) 1699-1704
55. Sayed-Ahmed M.M., Shouman S.A., Rezk B.M., Khalifa M.H., Osman A.M., and El-Merzabani M.M. Propionyl-l-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria. Pharmacol Res 41 (2000) 143-150
56. Shioji K., Kishimoto C., Nakamura H., et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106 (2002) 1403-1409
57. Bonfante V., Bonadonna U., Villani F., Di Fronzo U., Martini A., and Casazza A.M. Preliminary phase 1 study of 4′-epiadriamycin. Cancer Treat Rep 63 (1979) 915-918
58. Arcomone F., Penco S., Vigevani A., et al. Synthesis and antitumor properties of new glycosides of daumonycine and adriamycine. J Med Chem 18 (1975) 703-707
59. Casazza A.M., Di Marco A., and Bertazzoli C. Antitumor activity, toxicity and pharmacological properties of 4′-epi-adriamycin. In: Siegenthaler A., and Luthy R. (Eds). Current chemotherapy (1988), American Society for Microbiology, Washington, DC 1257-1260
60. Young C.W. Epirubicin, a therapeutically active doxorubicin analogue with reduced cardiotoxicity. In: Bonadonna U. (Ed). Advances in anthracycline chemotherapy: epirubicin (1984), Masson, Milan 183-188
61. Praet M., and Ruysschaert J.M. In-vivo and in-vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives. Biochim Biophys Acta 1149 (1993) 79-85
62. Milei J., Ale J.J., Garay G., et al. Hemodynamic effects of chronic 4′epi-adriamycin administration. Cardiovasc Drugs Ther 4 (1990) 1519-1523
63. Llesuy S.F., Milei J., Gonzalez Flecha B.S., and Boveris A. Myocardial damage induced by doxorubicins: hydroperoxide-initiated chemiluminescence and morphology. Free Radic Biol Med 8 (1990) 259-264
64. Kim C., Kim N., Joo H., et al. Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 46 (2005) 200-210
65. Vora J., Khaw B.A., Narula J., and Boroujerdi M. Protective effect of butylated hydroxyanisole on adriamycin-induced cardiotoxicity. J Pharm Pharmacol 48 (1996) 940-944
66. Morishima I., Okumura K., Matsui H., et al. Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant. J Pineal Res 26 (1999) 204-210
67. Abraham S.A., Waterhouse D.N., Mayer L.D., Cullis P.R., Madden T.D., and Bally M.B. The liposomal formulation of doxorubicin. Methods Enzymol 391 (2005) 71-97
68. Campos S. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. Oncologist 8 (2003) 10-16
69. Ewer M.S., Martin F.J., Henderson C., Shapiro C.L., Benjamin R.S., and Gabizon A.A. Cardiac safety of liposomal anthracyclines. Semin Oncol 31 (2004) 161-181
70. Herman E.H., Rahman A., Ferrans V.J., Vick J.A., and Schein P.S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 43 (1983) 5427-5432
71. Waterhouse D.N., Tardi P.G., Mayer L.D., and Bally M.B. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24 (2001) 903-920
72. Veldman R.J., Koning G.A., van Hell A., et al. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin. J Pharmacol Exp Ther 315 (2005) 704-710
73. Quiles J.L., Huertas J.R., Battino M., Mataix J., and Ramirez-Tortosa M.C. Antioxidant nutrients and adriamycin toxicity. Toxicology 180 (2002) 79-95
74. Sarter B. Coenzyme Q10 and cardiovascular disease: a review. J Cardiovasc Nurs 16 (2002) 9-20
75. Zhou G.Y., Zhao B.L., Hou J.W., Ma G.E., and Xin W.J. Protective effects of sodium tanshinone IIA sulphonate against adriamycin-induced lipid peroxidation in mice hearts in vivo and in vitro. Pharmacol Res 40 6 (Dec 1999) 487-491
76. Gnanapragasam A., Ebenezar K.K., Sathish V., Govindaraju P., and Devaki T. Protective effect of centella asiatica on antioxidant tissue defense system against adriamycin induced cardiomyopathy in rats. Life Sci 76 (2004) 585-597
77. Siveski-Iliskovic N., Kaul N., and Singal P.K. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89 (1994) 2829-2835
78. Singal P.K., Iliskovic N., Li T., and Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 11 (1997) 931-936
79. Myers C.E., McGuire W.P., and Young R. Adriamycin: amelioration of toxicity by tocopherol. Cancer Treat Rep 60 (1976) 961-962
80. Singal P.K., and Tong J.U. Vitamin E deficiency accentuates adriamycin-induced cardiomyopathy and cell surface changes. Mol Cell Biochem 84 (1988) 163-171
81. Breed J.G.S., Zimmerman A.N.B., Dormans J.A.M.A., and Pinedo H.M. Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. Cancer Res 40 (1980) 2033-2038
82. Herman E.H., and Ferrans V.J. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab Invest 49 (1983) 69-77
83. Wang Y.M., Madanat F.E., Kimball J.C., et al. Effect of vitamin E against adriamycin induced toxicity in rabbits. Cancer Res 40 (1980) 1022-1026
84. Legha S., Wang Y., Mackay B., et al. Clinical and pharmacologic investigation of the effects of alfa-tocopherol on adriamycin cardiotoxicity. In: Lubin B., and Machlin L. (Eds). Vitamin E: biochemical, hematological and clinical aspects. Ann N Y Acad Sci vol. 393 (1982) 411-417
85. Ferrans V.J., and Van Vleet J.F. Cardiac lesions of selenium-vitamin E deficiency in animals. Heart Vessels 1 (1985) 294-297
86. Guarnieri C., Flamigni E., and Rossoni-Caldarera C. Myocardial mitochondrial functions in alfa-tocopherol deficient and refed rabbits. In: Chazov E., Smirnov V., and Dhalla N.S. (Eds). Advances in myocardiology vol. 3 (1982), Plenum Publishing, New York 621-627
87. Fiamigni E., Guarnieri C., Toni C., and Caldarera C.M. Effect of oxygen radicals on heart mitochondrial function in alfa-tocopherol deficient rabbits. Int J Vitam Nutr Res 52 (1982) 402-406
88. Van Vleet J.F., Greenwood L., Ferrans V.J., and Rebar A.H. Effect of selenium and vitamin E on adriamycin-induced cardiomyopathy in rabbits. Ann J Vet Rev 39 (1978) 997-1010
89. Bertazzoli C., Sala L., and Solcia E. Experimental adriamycin cardiotoxicity prevented by ubiquinone "in vivo" rabbits. Int Res Commun Syst Med Sci 3 (1975) 468
90. Milei J., Boveris A., Molina H., Llesuy S., Storino R., and Milei S.E. Prenylamine inhibition of adriamycin-induced myocardiopathy. Acta Cardiol 40 (1985) 383-396
91. Murphy J.E. Drug profile: synadrin (prenylamine). J Int Med Res 1 (1973) 204-208
92. Milei J., Vazquez A., Boveris A., et al. The role of prenylamine in the prevention of adriamycin-induced cardiotoxicity. A review of experimental and clinical findings. J Int Med Res 16 (1988) 19-30
93. Milei J., Marantz A., Ale J., Vazquez A., and Buceta J.E. Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv 4 (1987) 129-136
94. Nakamae H., Tsumura K., Terada Y., et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer (Oct 24 2005) [ahead of print]
95. Tokudome T., Mizushige K., Noma T., et al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 36 (2000) 361-368
96. Rohde L.E., Bello-Klein A., Pereira R.P., et al. Superoxide dismutase activity in adriamycin-induced cardiotoxicity in humans: a potential novel tool for risk stratification. J Card Fail 11 (2005) 220-226
97. Li H.L., Liu B., Zhou L.W., and Yu W.H. Change and significance of nuclear factor-kappaB in adriamycin induced cardiomyopathy in rats. Chin Med J 118 (2005) 111-115
98. Brown H.R., Ni H., Benavides G., et al. Correlation of simultaneous differential gene expression in the blood and heart with known mechanisms of adriamycin-induced cardiomyopathy in the rat. Toxicol Pathol 30 (2002) 452-469
99. Lu P. Monitoring cardiac function in patients receiving doxorubicin. Semin Nucl Med 35 (2005) 197-201